摘要
目的 分析西格列汀治疗2型糖尿病的临床效果及对患者肾功能的影响,为2型糖尿病的临床治疗提供新依据。方法 选择2013年11月至2015年11月本院收治的100例2型糖尿病患者为研究对象,按照随机数表法将入选患者分为观察组和对照组,每组各50例。观察组患者采用西格列汀治疗,对照组患者采用阿卡波糖治疗。比较两组患者治疗前后血糖指标[空腹血糖（FBG）、餐后2小时血糖（2h PG）、糖化血红蛋白（Hb A1c）]、肾功能指标[尿微量白蛋白（UMA）、尿素氮（BUN）、血肌酐（Scr）]、肝功能指标[（谷丙转氨酶（ALT）、谷草转氨酶（AST）、乳酸脱氢酶（LDH）]及不良反应发生情况。结果 1血糖指标：治疗后两组患者FBG、2h PG、Hb A1c水平均较治疗前显著降低（P〈0.05）,观察组患者上述血糖指标水平均显著低于对照组（P〈0.05）;2肾功能指标：治疗后两组患者UMA、BUN、Scr水平均较治疗前显著下降（P〈0.05）,观察组患者上述肾功能指标水平均显著低于对照组（P〈0.05）;3肝功能指标：治疗前后两组患者肝功能指标组间及组内比较差异均无显著性（P〉0.05）;4不良反应：观察组患者3例发生低血糖反应,总并发症发生率为6.00%,对照组患者3例发生低血糖反应,1例发生过敏反应,总并发症发生率为8.00%;两组患者不良反应发生率比较差异无显著性（χ~2=0.1536,P〉0.05）。结论 西格列汀能够全面、有效地控制2型糖尿病患者血糖水平,同时对患者肾功能具有保护作用,具有良好的临床应用价值。
Objective To analyze the effect of sitagliptin on the clinical efficacy and renal function of patients with type 2 diabetes mellitus, and to provide a new basis for clinical treatment of type 2 diabetes mellitus. Method 100 cases of patients with type 2 diabetes mellitus from November 2013 to November 2015 in our hospital were selected as research objects and they were randomly divided into observation group and control group, 50 cases in each group. Observation group patients were given sitagliptin oral treatment, control group patients were treated with acarbose. The general information, blood glucose indexes [fasting blood glucose（FBG）, 2-hour plasma glucose（2h PG）, Hb A1c], renal function indexes [urine micro-albumin（UMA）, blood urea nitrogen（BUN）, serum creatinine（Scr）], liver function indexes（ALT, AST, LDH） and adverse reactions were compared and analyzed between the two groups. Result 1 blood glucose indexes： after treatment, the levels of FBG, 2h PG, Hb A1 c of the two groups were significantly decreased（P〈0.05）, but these indexes of observation group were significantly lower than control group（P〈0.05）; 2 renal function indexes： the levels of UMA, BUN, Scr were significantly decreased in both groups after treatment（P〈0.05）, and control group patients had better renal function than observation group（P〈0.05）; 3 liver function indexes showed no difference before and after treatment between the two groups（P〉0.05）; 4 adverse reaction： observation group had 3 cases of hypoglycemia, the total incidence was 6.00%, control group had 3 cases of hypoglycemia, 1 case of allergic reactions, the total incidence was 8.00%, and there was no significant difference between the two groups（P〉0.05）. Conclusion Sitagliptin in the treatment of type 2 diabetes can effectively control the blood glucose indexes with additional benefits of protective effect on renal function, worthy of popularizing in clinical.
出处
《中国医学前沿杂志（电子版）》
2016年第9期169-172,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词
西格列汀
2型糖尿病
肾功能
Sitagliptin
Type 2 diabetes mellitus
Renal function
